Press Releases

A clinical trial underway at Roswell Park Comprehensive Cancer Center will assess a brand-new immunotherapy approach in patients with cancer of the ovaries, fallopian tubes or peritoneum that has recurred despite earlier treatment.

James D. Newman has been named the new Chair of the Roswell Park Alliance Foundation, the 501(c)(3) not-for-profit organization that manages all donations made to Roswell Park Comprehensive Cancer Center.

Generous donations have set in motion five groundbreaking new research projects at Roswell Park Comprehensive Cancer Center this spring.

Roswell Park Comprehensive Cancer Center has added a new leader to its Department of Pathology and Laboratory Medicine with the promotion of Paul Bogner, MD, to Director of Surgical Pathology.

Roswell Park Comprehensive Cancer Center and Oneida Healthcare have received a $1 million gift from an anonymous donor to their joint capital campaign.

One of the mechanisms that makes so-called triple-negative breast cancer (TNBC) notoriously aggressive and hard to treat is its ability to disarm proteins that suppress tumors and mutate them into tumor drivers. Seeking to better understand this process, a team from Roswell Park Comprehensive Cancer Center decided to focus not on what these TNBC tumors lack but something they possess: an alternate estrogen receptor, ER-beta. In a new article in JNCI: Journal of the National Cancer Institute, they report that a widely used breast cancer drug, tamoxifen, can turn the ER-beta protein into a double agent capable of disrupting the processes that typically make TNBC tumors so devastating.

Researchers have observed for several years that people who have a history of using oral contraceptives are less likely to develop ovarian cancer. A team from Roswell Park Comprehensive Cancer Center analyzed those connections more deeply, reporting for the first time that the protective benefit of oral contraceptives is most pronounced with the most aggressive and fatal subtypes of ovarian cancer.